Pfizer (PFE) Navigates Patent Losses With Strategic Cost Controls, BMO Capital Reaffirms Outperform Rating

Pixabay/Public Domain

Pfizer Inc. (NYSE:PFE) besides forecasted a $1.5 cardinal year-over-year simplification successful income erstwhile definite medications mislaid marketplace exclusivity. Some blockbuster treatments, specified arsenic the company’s pneumonia vaccination Prevnar, are seeing stronger rivalry from competitors.

BMO observed that Pfizer’s softer 2026 projection is mostly driven by prolonged uncertainty successful its Covid business, which is expected to autumn 23% year-over-year to astir $5 cardinal successful full revenue.

BMO anticipates that aboriginal talks volition halfway connected Pfizer’s caller acquisition of Metsera and the company’s efforts to present ongoing outgo savings, which person already exceeded their 2025 projections.

Pfizer Inc. (NYSE:PFE) is simply a planetary biopharmaceutical institution that manufactures, develops, markets, and sells biopharmaceutical products worldwide. It advances wellness, prevention, treatment, and cures successful processing and emerging markets.

While we admit the imaginable of PFE arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.

Disclosure: None. This nonfiction is primitively published at Insider Monkey.